TCRT

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a clinical-stage biotechnology company focused on developing innovative cancer treatments through engineered cell therapies. Originally founded as ZIOPHARM Oncology in 2003 and renamed Alaunos Therapeutics in January 2022, the Houston-based company has evolved from a traditional oncology drug developer into a specialized cell therapy company. The company went public in 2005 and has since pivoted to focus exclusively on adoptive T-cell receptor (TCR) engineered T-cell therapies for treating solid tumors, representing a cutting-edge approach in cancer immunotherapy.